quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:11:54·42d
SECFiling
Allogene Therapeutics Inc. logo

SEC Form 10-K filed by Allogene Therapeutics Inc.

ALLO· Allogene Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ALLO
    Allogene Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 16UpdateAnalyst-
  • Apr 10UpdateJefferies$6.00
  • Jan 9UpdateCitizens JMP$5.00
  • Oct 10UpdateAnalyst-
  • May 14UpdateCitizens JMP-
  • Mar 14UpdateCitizens JMP$5.00

Related

  • INSIDER15h
    SVP, Finance Yoshiyama Annie sold $22,144 worth of shares (9,586 units at $2.31), decreasing direct ownership by 7% to 124,517 units (SEC Form 4) to satisfy withholding tax
  • PR2d
    Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
  • SEC3d
    SEC Form PRE 14A filed by Allogene Therapeutics Inc.
  • PR3d
    Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
  • PR7d
    Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
  • ANALYST7d
    Allogene upgraded by Analyst
  • SEC8d
    SEC Form 8-K filed by Allogene Therapeutics Inc.
  • SEC8d
    SEC Form 424B5 filed by Allogene Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022